orsus therapeutics plc
orsus therapeutics plc Company Information
Company Number
13374907
Next Accounts
Dec 2025
Shareholders
l i a pure capital ltd - kfir silberman
silvi uziel
View AllGroup Structure
View All
Industry
Manufacture of basic pharmaceutical products
+1Registered Address
14 belvoir road, london, SE22 0QY
Website
-orsus therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ORSUS THERAPEUTICS PLC at £0 based on a Turnover of £0 and 0.93x industry multiple (adjusted for size and gross margin).
orsus therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ORSUS THERAPEUTICS PLC at £0 based on an EBITDA of £-104.7k and a 4.79x industry multiple (adjusted for size and gross margin).
orsus therapeutics plc Estimated Valuation
Pomanda estimates the enterprise value of ORSUS THERAPEUTICS PLC at £439.5k based on Net Assets of £237k and 1.85x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Orsus Therapeutics Plc Overview
Orsus Therapeutics Plc is a live company located in london, SE22 0QY with a Companies House number of 13374907. It operates in the manufacture of other food products n.e.c. sector, SIC Code 10890. Founded in May 2021, it's largest shareholder is l i a pure capital ltd - kfir silberman with a 14.6% stake. Orsus Therapeutics Plc is a startup, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Orsus Therapeutics Plc Health Check
Pomanda's financial health check has awarded Orsus Therapeutics Plc a 2.5 rating. We use a traffic light system to show it exceeds the industry average on 2 measures and has 1 areas for improvement. Company Health Check FAQs
2 Strong
1 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Orsus Therapeutics Plc
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Orsus Therapeutics Plc
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Orsus Therapeutics Plc
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Orsus Therapeutics Plc
- - Industry AVG
Employees
with 1 employees, this is below the industry average (110)
- Orsus Therapeutics Plc
- - Industry AVG
Pay Structure
on an average salary of £52.4k, the company has an equivalent pay structure (£52.4k)
- Orsus Therapeutics Plc
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Orsus Therapeutics Plc
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Orsus Therapeutics Plc
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Orsus Therapeutics Plc
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Orsus Therapeutics Plc
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 310 weeks, this is more cash available to meet short term requirements (7 weeks)
- - Orsus Therapeutics Plc
- - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 15.8%, this is a lower level of debt than the average (49.9%)
- - Orsus Therapeutics Plc
- - Industry AVG
ORSUS THERAPEUTICS PLC financials
Orsus Therapeutics Plc's latest turnover from June 2024 is 0 and the company has net assets of £237 thousand. According to their latest financial statements, we estimate that Orsus Therapeutics Plc has 1 employee and maintains cash reserves of £266.1 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2024 | Jun 2023 | Jun 2022 | |
|---|---|---|---|
| Turnover | |||
| Other Income Or Grants | |||
| Cost Of Sales | |||
| Gross Profit | |||
| Admin Expenses | |||
| Operating Profit | |||
| Interest Payable | |||
| Interest Receivable | 1 | ||
| Pre-Tax Profit | -88,929 | -76,238 | -4,195 |
| Tax | |||
| Profit After Tax | -88,929 | -76,238 | -4,195 |
| Dividends Paid | |||
| Retained Profit | -88,929 | -76,238 | -4,195 |
| Employee Costs | |||
| Number Of Employees | |||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2024 | Jun 2023 | Jun 2022 | |
|---|---|---|---|
| Tangible Assets | |||
| Intangible Assets | |||
| Investments & Other | |||
| Debtors (Due After 1 year) | |||
| Total Fixed Assets | |||
| Stock & work in progress | |||
| Trade Debtors | |||
| Group Debtors | 15,500 | 4,500 | 6,863 |
| Misc Debtors | 40,000 | ||
| Cash | 266,097 | 335,146 | 241,371 |
| misc current assets | |||
| total current assets | 281,597 | 339,646 | 288,234 |
| total assets | 281,597 | 339,646 | 288,234 |
| Bank overdraft | |||
| Bank loan | |||
| Trade Creditors | |||
| Group/Directors Accounts | 27,029 | 5,029 | 11,029 |
| other short term finances | |||
| hp & lease commitments | |||
| other current liabilities | 17,530 | 8,650 | |
| total current liabilities | 44,559 | 13,679 | 11,029 |
| loans | |||
| hp & lease commitments | |||
| Accruals and Deferred Income | |||
| other liabilities | |||
| provisions | |||
| total long term liabilities | |||
| total liabilities | 44,559 | 13,679 | 11,029 |
| net assets | 237,038 | 325,967 | 277,205 |
| total shareholders funds | 237,038 | 325,967 | 277,205 |
| Jun 2024 | Jun 2023 | Jun 2022 | |
|---|---|---|---|
| Operating Activities | |||
| Operating Profit | |||
| Depreciation | |||
| Amortisation | |||
| Tax | |||
| Stock | |||
| Debtors | 11,000 | -42,363 | 46,863 |
| Creditors | |||
| Accruals and Deferred Income | 8,880 | 8,650 | |
| Deferred Taxes & Provisions | |||
| Cash flow from operations | |||
| Investing Activities | |||
| capital expenditure | |||
| Change in Investments | |||
| cash flow from investments | |||
| Financing Activities | |||
| Bank loans | |||
| Group/Directors Accounts | 22,000 | -6,000 | 11,029 |
| Other Short Term Loans | |||
| Long term loans | |||
| Hire Purchase and Lease Commitments | |||
| other long term liabilities | |||
| share issue | |||
| interest | 1 | ||
| cash flow from financing | 22,001 | 119,000 | 292,429 |
| cash and cash equivalents | |||
| cash | -69,049 | 93,775 | 241,371 |
| overdraft | |||
| change in cash | -69,049 | 93,775 | 241,371 |
orsus therapeutics plc Credit Report and Business Information
Orsus Therapeutics Plc Competitor Analysis
Perform a competitor analysis for orsus therapeutics plc by selecting its closest rivals, whether from the MANUFACTURING sector, other startup companies, companies in SE22 area or any other competitors across 12 key performance metrics.
orsus therapeutics plc Ownership
ORSUS THERAPEUTICS PLC group structure
Orsus Therapeutics Plc has 3 subsidiary companies.
Ultimate parent company
ORSUS THERAPEUTICS PLC
13374907
3 subsidiaries
orsus therapeutics plc directors
Orsus Therapeutics Plc currently has 5 directors. The longest serving directors include Mr Aditya Chathli (May 2021) and Mr Dwight Mighty (May 2021).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Aditya Chathli | England | 59 years | May 2021 | - | Director |
| Mr Dwight Mighty | England | 64 years | May 2021 | - | Director |
| Adi Zuloff-Shani | England | 56 years | Nov 2021 | - | Director |
| Mr Callum Sommerton | England | 29 years | Jan 2025 | - | Director |
| Mr Nicholas Tulloch | England | 52 years | Jan 2025 | - | Director |
P&L
June 2024turnover
0
0%
operating profit
-104.7k
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
237k
-0.27%
total assets
281.6k
-0.17%
cash
266.1k
-0.21%
net assets
Total assets minus all liabilities
Similar Companies
orsus therapeutics plc company details
company number
13374907
Type
Public limited with Share Capital
industry
21100 - Manufacture of basic pharmaceutical products
10890 - Manufacture of other food products n.e.c.
incorporation date
May 2021
age
4
incorporated
UK
ultimate parent company
accounts
Full Accounts
last accounts submitted
June 2024
previous names
orsus therapeutics limited (October 2022)
accountant
-
auditor
POINTON YOUNG
address
14 belvoir road, london, SE22 0QY
Bank
-
Legal Advisor
-
orsus therapeutics plc Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to orsus therapeutics plc.
orsus therapeutics plc Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for ORSUS THERAPEUTICS PLC. This can take several minutes, an email will notify you when this has completed.
orsus therapeutics plc Companies House Filings - See Documents
| date | description | view/download |
|---|
